13G Filing: Matrix Capital Management and Adaptimmune Therapeutics PLC – ADR (ADAP)

Page 4 of 8 – SEC Filing

Item 1(a). NAME OF ISSUER.
The name of the issuer is Adaptimmune Therapeutics PLC (the “Company“).
Item 1(b). ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES:
The Company’s principal executive offices are located at 60 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire OX14 4RX, United Kingdom.
Item 2(a). NAME OF PERSON FILING:
This statement is filed by:
(i)

Matrix Capital Management Company LP (the “Investment Manager”),
a Delaware limited partnership, and the investment adviser to Matrix Capital Management Master Fund, LP (the “Matrix Fund”),
with respect to the Shares (as defined in Item 2(d) below) represented by the ADSs directly held by the Matrix Fund; and

(ii) Mr. David E. Goel (the “Mr. Goel“), the Managing General Partner of the Investment Manager, with respect to the Shares represented by the ADSs directly held by the Matrix Fund.
The foregoing persons are hereinafter sometimes collectively referred to as the “Reporting Persons.”
The filing of this statement should not be construed as an admission that any of the forgoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the Shares reported herein.
Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
The address of the business office of each of the Reporting Persons is Bay Colony Corporate Center, 1000 Winter Street, Suite 4500, Waltham, MA 02451.
Item 2(c). CITIZENSHIP:
The Investment Manager is a Delaware limited partnership.  Mr. Goel is a citizen of the United States.
Item 2(d). TITLE OF CLASS OF SECURITIES:
Ordinary Shares, par value £0.001 (the “Shares“).

Follow Adaptimmune Therapeutics Plc (NASDAQ:ADAP)